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ABSTRACT 
Representing an evolving and diverse group of syndromes, immunodeficiencies can currently 
be viewed as a spectrum of disorders where a dysfunction of the immune system plays a 
significant etiologic role. Cytotoxic lymphocytes are immune cells that are pivotal for the 
eradication of infected and malignant cells. They also contribute to immune-regulation. 
Congruently, patients with defects in cytotoxic lymphocyte function show increased 
susceptibility to infections, malignancies and inflammation.  
This work focuses on the role of cytotoxic lymphocytes in syndromes where their 
pathophysiological involvement is suspected, but not established. The first study investigates 
the variability in cytotoxic effector functions introduced by commonly used pharmacological 
substances, knowledge that is important for the interpretation of patient data. The second 
study establishes a robust and sensitive addition to the arsenal of diagnostic assays for 
cytotoxic lymphocyte dysfunctions. The third study shows that myalgic 
encephalomyelitis/chronic fatigue syndrome (ME/CFS), linked to viral infections and 
hypothesized to be caused by immune dysregulation, is not a syndrome where a substantial 
fraction of the patients has any obvious primary defect in lymphocyte cytotoxicity. The fourth 
and the fifth studies identify and functionally dissect the impact of autoantibodies directed 
against an inhibitory cytotoxic lymphocyte receptor, NKG2A, in patients with systemic lupus 
erythematosus (SLE), an autoimmune disorder. In summary, the studies expand our 
knowledge and toolbox for assessing lymphocyte cytotoxicity and highlight the complexity 
of interpreting experiments investigating cytotoxic lymphocyte function in the context of 
chronic immunodeficiency disorders. Furthermore, they provide clinically relevant insights 
about the role of cytotoxic lymphocytes in both ME/CFS and SLE. 
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  1 
FOREWORD AND PRESENTATION OF MAXIMS 
In this doctoral thesis, I have tried to condense a substantial portion of the scientific work that 
I (and all my collaborators) have performed over the last years. To add some of the historical 
weight that a doctoral thesis merits and to hopefully make the reading more enjoyable, I have 
tried to sum up the principles that have guided my work in the following five maxims: 
 
Salutogenetic insight can be gained by finding 
the traits defining each group of ill 
 
For each uncommon, severe illness 
there is a common, subtle counterpart 
 
A step towards controlled constancy lies in 
understanding the grounds of variability 
 
The subtle in the macrocosm may be discerned by 
finding the robust in the microcosm 
 
The regular nature of an illness may be understood 
by exploring its rare causes 
 
The following introductory section is meant for someone not immediately working in this 
subfield of immunology. It provides a frame in which the studies, underpinned by these 
maxims, have been performed. It is succeeded by a section where the studies will be 
summarized and discussed, which is followed by conclusions.  
I sincerely hope that you, dear reader, during and after getting acquainted with cytotoxic 
lymphocytes in this context, will feel as enthusiastic about them as I have been during the 
nine years in which I have had the opportunity to investigate them and their multifaceted 
functions.  
  2 
LIST OF ABBREVIATIONS 
ADCC  Antibody-dependent cellular cytotoxicity 
CD  Cluster of differentiation (taxonomic term for classification of 
immunologic surface proteins) 
CMV   Cytomegalovirus 
CTL  Cytotoxic T lymphocyte 
DNAM-1  DNAX accessory molecule 1 
EAT-2  Ewing sarcoma/FLI1 Activated Transcript 2 
EBV  Epstein-Barr Virus 
Fc  Fragment crystallizable (the non-variable part of an antibody) 
HLA  Human leucocyte antigen 
HLH  Hemophagocytic lymphohistiocytosis 
IFN  Interferon 
ITIM  Immunoreceptor tyrosine-based inhibitory motif 
ITAM  Immunoreceptor tyrosine-based activating motif 
ICAM  Intercellular adhesion molecule 
KIR  Killer-cell immunoglobulin-like receptor 
LFA-1  Leucocyte functional antigen 1 
ME/CFS  Myalgic encephalomyelitis/chronic fatigue syndrome  
MHC  Major histocompatibility complex 
NK  Natural killer 
NKG2  Natural Killer Group 2 
PBMC  Peripheral blood mononuclear cells 
pDC  Plasmacytoid dendritic cell 
PLZF  Promyelocytic leukemia Zink finger protein 
RNA-IC  RNA-immune complex 
SLAM  Signaling lymphocytic activation molecule 
SLE  Systemic lupus erythematosus 





Salutogenetic insight can be gained by finding 
the traits defining each group of ill 
 
This, the first and most general maxim of this work summarizes one central motivation to 
conduct human medical research. The family of immunological research approaches 
following from this maxim have together been termed Immunology in Natura (1). With these 
approaches, the immune systems of relevant patients, patient groups or populations are 
studied to gain insights of the immunologic causes for their disease. When such a cause is 
identified, it does not only help to explain the etiology of the disease (pathogenesis), but also 
sheds light on the very components of the immune system that are necessary to keep the rest 
of humanity from succumbing to the same disease – in other words, points to the etiology of 
our healthiness (salutogenesisi). The proponents of Immunology in Natura claim that the 
large variability in genetic backgrounds and environmental exposures in the human 
population provides the optimal framework for identifying such immunological defects, as 
disease-correlated immune aberrances are likely to be ecologically relevant, i.e. non-
redundant in a natural setting (1). That such genetic variability is present within any wild 
population is due to fierce competition between hosts and pathogens; a genetic variant that 
proves to be a selective advantage towards a certain pathogen might prove deleterious in the 
interaction with another. Thus, genetic variants tend not to spread to the whole population or 
species, but rather be confined to a subgroup, the size of which fluctuates depending on the 
current pathogenic pressure.  
Traditionally, basic immunological research has primarily utilized experimental animal 
models, such as inbred mice with aseptic living conditions. Such systems have provided 
numerous insights and are essential in answering questions of causality, as they allow control 
over genetic and environmental variation and arguably make in vivo experiments less 
ethically inacceptable than they would be in humans. Yet, experimental animal models 
almost by definition lack the aforementioned genetic variability and complex environmental 
exposure patterns typical to a wild population such as humanity. Furthermore, many immune 
genes are among the most rapidly evolving in our genome, again due to environmental 
adaptations following pathogen-host competition and coevolution. Accordingly, while large 
                                                
i Here, the term salutogenesis is used in its most general meaning, deviating away from the original, 
psychological sense-of-coherence concept introduced together with the term by Aaron Antonovsky 
(2). 
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parts of the genetic composition dictating the shape of the immune system are conserved 
among most vertebrates, certain important discrepancies exist even between mammal species. 
Thus, it has been argued that previous approaches, where phenomena have been identified in 
model systems and then confirmed or denied in studies on humans should be complemented 
with Immunology in Natura-research followed by verifications of causality in model systems 
(1). 
One approach under the Immunology in Natura umbrella is epidemiological. This is 
motivated by the observation that the variability in genetic background and environmental 
exposures among humans combined with our sheer numbers provides an extraordinary 
opportunity to find small groups that, due to similar genetic aberrances and environmental 
triggers, end up with specific disease. Practically, patient groups with similar clinical 
characteristics are investigated, in search for immunological abnormalities that distinguish 
these patients from healthy populations. When such an abnormality is identified, this 
knowledge might generate a clue about the cause of the disorder. Consequently, it might also 
suggest that the abnormal immunological parameter is likely to be directly or indirectly 
involved in counteracting development of the disorder under normal conditions. Thus, this 
approach, when successful, provides both clinically and biologically relevant results. In this 
work, all studies are performed with this Immunology in Natura approach in mind. Now, to 
be able to further describe and discuss details, a general introduction of the immune system is 
necessary. 
 
1.1 THE IMMUNE SYSTEM: A BASIC INTRODUCTION TO AN EVOLVING 
WEB OF DEFENSE SYSTEMS 
Organisms on all levels of complexity have developed strategies to cope with infectious 
challenges and maintain homeostasis, enabling growth and reproduction. An integral part of 
keeping homeostasis is counteracting occupation by pathological entities. Representing the 
simplest cellular organisms, bacteria have numerous strategies to avoid being turned into 
factories of viral proteins by bacteriophages (3,4). In more complex organisms, all cells, 
regardless of their specialized role, have intrinsic mechanisms to sustain homeostasis and 
sense infection. In addition, multicellular organisms tend to dedicate a complex system of 
functions to the prevention of invasion by a variety of potential pathological entities, such as 
bacteria, viruses, parasites and malignant cells. This complex system of functions is 
commonly denoted the immune system and congruently, the cells carrying out specialized 
immune functions are entitled immune cells.  
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A central feature of all arms of immune systems is the ability to differentiate between 
normal cells or molecules within or closely associated to the organism, referred to as “self”, 
and other cells or molecules, referred to as “non-self”. One widely disseminated solution for 
this is maintaining a set of intra- and extracellular receptors that sense conserved pathogen-
associated molecular patterns (5). In addition, the immune system identifies aberrant or 
stressed endogenous cells. This is in some cases done by detecting “induced-self” (6), i.e. 
molecules that are up-regulated on cells upon stress, and in other cases by identifying 
damage-associated molecular patterns, such as nuclear proteins or DNA in the extracellular 
space (5). These pattern recognition receptors are germ line encoded, and as such evolve 
along with the hosts. As they are constant during the life of an individual host, they are 
considered innate immune receptors. The pattern recognition concept is central to the 
function of all innate immune cells, such as granulocytes, monocytes, macrophages, dendritic 
cells and innate lymphoid cells. Each innate immune cell expresses a multitude of receptors 
with different specificities, which enables it to respond immediately upon numerous different 
challenges. 
About 500 million years ago, a second arm of the immune system likely first emerged in 
the ancestors of the simplest present-day vertebrate animals, such as hag fish or lampreys (7). 
The common feature of the cells in this arm is their ability to confer memory of previous 
pathogen exposures in the individual host, thus mounting potent recall responses upon 
secondary challenge. This part of the immune system is congruently called “adaptive”. Soon 
after the first emergence of adaptive immunity in general, recombination activating genes (8) 
were spread and enabled somatic recombination (9), a process that is central to adaptive 
immune function in all higher vertebrates (7). Somatic recombination is a cellular process in 
which (two or) three gene segments, called variable (V), diversity (D) and joining (J), are 
pasted together by gene editing systems which create a new, combined V(D)J gene product 
(9). In a cell that has undergone somatic recombination, the V(D)J gene product codes a key 
receptor unique to that specific cell and all its clonal relatives. As multiple different variants 
of the V, D and J segments are present in any individuals genome, and as these are 
stochastically selected during somatic recombination, this process, in conjunction with a few 
additional gene editing systems, gives rise to the presence of at least tenths of millions of 
adaptive immune cell clones with unique receptors in a single human, capable of recognizing 
a wide diversity of antigens (10). As adaptive immune cells are subject to complex selection 
processes, a vast majority of the circulating cells recognize non-self-molecules and can, upon 
recognition of their antigen, respond by dividing rapidly and form a large force of cells 
targeted to the present pathogen. Thus, the adaptive immune cells provide a defense system 
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that dynamically change depending on the environment that the individual animal lives in. 
There are two major classes of adaptive immune cells. Bone marrow-derived (B) cells have 
receptors that directly recognize antigen in the extracellular space. Subsets of B cells can 
produce and release soluble forms of their receptors, called antibodies. Thymus-derived (T) 
cells instead recognize short preprocessed signal peptides presented on major 
histocompatibility complex (MHC) proteins (in humans, MHC is called human leucocyte 
antigen or HLA). Further, the two main, classical T-cell subsets are defined by their 
expression of the CD4 and CD8 co-receptors. These receptors define what source of antigen 
that the T-cell in question detects. CD4+ on T-cells enables TCR recognition of MHC class II 
(MHC-II, HLA-II in humans) presented peptides, which is expressed on immune cells with 
the special capacity to detect and break down pathological extracellular molecules. CD8+ T-
cells, on the other hand, can recognize MHC-I (HLA-I in humans) with their TCR. MHC-I is 
expressed on virtually all vertebrate nucleated cells and present peptides derived from the 
intracellular space. A random fraction of all proteins is processed and displayed on the MHC-
I molecules. Thus, T cells expressing CD8 mainly assess endogenous protein production. 
Taken together, the adaptive lymphocyte subsets can identify specific aberrant molecules 
present extracellularly or intracellularly from endogenous or exogenous cells.  
In summary, the innate and the adaptive arms of the immune system are complimentary 
in nature. The innate arm can, by always probing for a variety of the most prototypic 
pathological signals, respond rapidly to challenge by various pathogens. It compensates for 
its lower specificity and affinity for a certain pathogen-associated molecule with expressing 
diverse and numerous receptors on individual cells, giving rise to a high avidity for most 
pathogens. The adaptive cells, conversely, can after a few days of pathogenic challenge 
mount a tailored and strong response towards any molecule with high specificity and affinity. 
Instead of structuring the immune system based on means of recognition, one can view it 
from the angle of hematopoietic origins. In this division, there are also two main classes of 
cells: the myeloid and the lymphoid cells. The myeloid progenitor cells are arguably more 
pluripotent, not only giving rise multiple innate immune cell types such as granulocytes, 
monocytes, macrophages and dendritic cells, but also to erythrocytes and thrombocytes. 
Lymphoid progenitors, on the other hand, form the lymphocyte populations, both the 
adaptive B- and T cells and the innate lymphoid cells. 
A third way of dividing the immune system is based on the effector functions, which are 
broadly categorized as humoral or cellular. Cells active in humoral immunity produce soluble 
molecules (humoral coming from latin humor meaning ‘fluid’) such as complement factors, 
antimicrobial peptides and antibodies, that convey the effector functions in bodily fluids. 
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These molecules are primarily active in extracellular compartments and on cell surfaces. On 
the other hand, immune cells conferring cellular immunity directly identify and rid the body 
of aberrant cells, exogenous or endogenous, that are potentially pathological. In this work, the 
focus lies on a specific part of the cellular immune system; the cytotoxic lymphocytes. 
 
1.1.1 Cytotoxic lymphocytes – the terminators of the cellular immune system 
Cytotoxic lymphocytes are effector cells with the ability to identify and eradicate cells 
showing signs of pathological alteration, mainly due to either infections with intracellular 
pathogens or due to neoplastic transformation (11). They also play pivotal roles in controlling 
immune responses, i.e. by creating negative feedback loops through killing of activated 
immune cells that promote inflammation (12,13). In humans (and many animals), the two 
main subsets are the innate natural killer (NK) cells and the adaptive cytotoxic CD8+ T cells 
(11).  
 
1.1.2 Natural killer cells  
Natural killer cells are considered innate lymphoid cells, as their responses are regulated by a 
multitude of germ-line encoded receptors (14). Typically, during interaction with an 
individual target cell, multiple activating and inhibitory receptors are engaged. Hence, the 
functional outcome of a specific NK-target cell interaction is determined by receptor 
expression patterns and density on the NK cells (15) and, conversely, ligand expression 
patterns and density on the target cell (16). Further complicating the matter, a single ligand 
may bind both inhibitory and activating receptors (17,18). The following section is devoted to 
introducing a few of the NK cell receptors that play prominent roles in this work. 
One receptor that inhibits NK cell function is the natural killer group 2 A 
(NKG2A)/CD94 heterodimer (19,20). NKG2A is a type-2 transmembrane protein with an 
extracellular C-type lectin domain (21). Its intracellular domain contains an immunoreceptor 
tyrosine-based motif (ITIM) (22,23), that upon activation becomes phosphorylated and 
recruits phosphatases, that efficiently counteract an array of activating receptor signaling 
pathways (24). NKG2A/CD94 recognizes HLA-E, a relatively conserved, non-canonical 
HLA-I molecule that presents signal peptides from other HLA-I molecules (25–28). More 
specifically, only certain HLA-E/signal peptide combinations are stable on the cell surface 
(29) and recognized by NKG2A/CD94 (25,26). Accordingly, NKG2A-expressing NK cells 
are strongly inhibited by target cells that produce HLA proteins presented by HLA-E (16). 
This inhibition can only partially be overcome by the strongest activating stimuli (16). 
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However, in situations where endogenous cells evade T cell recognition by decreasing 
classical HLA-I expression, the HLA-E-signal peptide complexes will decrease consequently 
and the NK cell will no longer be inhibited by NKG2A/CD94. If the target cell expresses 
ligands for activating NK cell receptors in this situation, it will become susceptible to NK 
cell-mediated killing (16). In combination with the large group of inhibitory killer 
immunoglobulin receptors (KIRs), this function, called missing-self recognition, grant NK 
cells with a complimentary function to T cell-mediated, HLA-I-dependent surveillance and 
eradication of aberrant cells.  
The lectin-like receptor family encoded on human chromosome 12, to which NKG2A 
belongs, has multiple NKG2 receptor members. The closest homologue to NKG2A is 
NKG2C, sharing 94% of amino acid sequence in the external domain. The NKG2C/CD94 
complex is activating (22,23,30), as NKG2C does not have any intracellular signaling 
domain, but rather associates with the activating adaptor protein DAP12 (31). The 
NKG2C/CD94 complex also binds HLA-E, but with lower affinity than NKG2A/CD94 (32). 
This is due to differences in the contact area between CD94 and the NKG2 proteins and not 
directly in the HLA-E contact site (33). Still, different signal peptides give rise to different 
affinities (32). As NKG2A is mainly expressed on “undifferentiated” NK cells (34), and 
NKG2C preferentially is expressed upon pathogen challenge, especially cytomegalovirus 
(CMV) (35), these receptors are seldom co-expressed and generally have complimentary 
functions. Yet, in cases where they are co-expressed, the NKG2A signal overrides the 
NKG2C signal (36).  
This duality in the NK cell response to HLA-E recognition has been proposed to be 
linked to the defense against human CMV infection. One of many immune evasion 
mechanisms by CMV is the down-regulation of HLA-I expression (37). Potentially 
compensating for lack of HLA-I expression, CMV also expresses the protein UL40, which 
contains multiple sequences similar to those of classical HLA-I signal peptides. These 
peptides are presented by HLA-E and induce HLA-E up-regulation, inhibiting NK cell-
mediated killing via NKG2A/CD94 (38). NKG2C/CD94, on the other hand, can be engaged 
by HLA-E presenting UL40-derived peptides and kill the target cell anyway. However, this is 
dependent on the specific sequence of the UL40 protein as some UL40 peptides only elicit 
inhibition by NKG2A/CD94 without activating NKG2C-positive cells (39). 
A third member of the lectin-like receptor family is NKG2D. NKG2D is expressed on all 
human NK cells (40) and acts through intracellular association with the activating adaptor 
protein DAP10 (41). The signal resulting from ligand binding is not strong enough to trigger 
activation by itself, but only when other activating receptors are engaged simultaneously (42). 
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Therefore, NKG2D is considered a co-activating receptor (42). It only has a 21% amino acid 
homology to the other NKG2 receptors (21) and is expressed as a homodimer (41). Multiple 
ligands have been identified for human NKG2D (43), all of which are structurally related to 
HLA-I molecules, but lack peptide presenting capacity (43). NKG2D ligands can be up-
regulated by cellular stress, and NKG2D is, accordingly, one of the “induced-self” receptors 
(6). In an evolutionary perspective, the multitude of ligands for NKG2D may reflect an 
immunological “arms race” between hosts and viruses (44): as a viral infection gives rise to 
cellular stress and hence NKG2D ligand up-regulation, some viruses, such as CMV, produce 
proteins that interfere with up-regulation of NKG2D-ligands (44). This has in turn led to 
NKG2D ligand gene multiplication and mutation events, circumventing this interference, 
leading the viruses to further adapt, and so on. As a result, animal species differ in the number 
of NKG2D ligands and extent of their diversity (44). 
Examples of other receptors that sense “induced-self” are DNAX accessory molecule 1 
(DNAM-1) and the signaling lymphocytic activation molecule (SLAM) family of receptors.  
DNAM-1 is an adhesion molecule and a member of the Ig-like family of glycoproteins 
(45). It is expressed on a majority of human NK cells. It is activating (45) and, like NKG2D, 
works as a co-activating receptor in humans (42). It signals through the adaptor molecule 
Grb2 (46) and needs to be physically associated to the leucocyte functional antigen 1 (LFA-1, 
see section 1.1.5) to be functional (47). DNAM-1 binds CD112 and CD155, which both serve 
as viral receptors (48) and are up-regulated upon cellular stress and on neoplastic cells 
(48,49). Of note, a number of inhibitory receptors with similar ligand binding profiles as 
DNAM-1 have been identified (18). 
The SLAM family is a group of CD2-related receptors. In human NK cells, they 
generally signal through both the activating adaptors SLAM Associated Protein and Ewing 
Sarcoma/FLI1 Activated Transcript 2 (EAT-2) (50). In cell types where these adaptors are 
not present, including immature NK cells, the receptors are instead generally inhibitory in 
nature, due to intracellular recruitment of phosphatases (50). Of the receptors in the family, 
CD48, CD84, CD244 (2B4), CD229 (LY9), CD319 (CRACC) and CD352 (NTB-A) are 
expressed by NK cells (VI). Apart from CD244 which binds CD48, the SLAM family of 
receptors interact homotypically (50). They are upregulated upon cellular activation (VI, 51) 
and accordingly contribute to recognition of “induced self”. 
NK cells also express the low-affinity Fc-receptor CD16 (FcgRIIIA) (52). This receptor 
is activating, through intracellular association with the immunoreceptor tyrosine-based 
activating motif (ITAM)-containing adaptor proteins CD3z and FceRg (53). CD16 differs 
from all other NK cell receptors in that engagement of this receptor alone is sufficient to 
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induce release of cytotoxic granules (42). Thus, NK cells are likely to kill antibody-opsonized 
target cells. This process is called antibody-dependent cellular cytotoxicity (ADCC) and it 
provides a link between NK cells and the adaptive humoral immune system and to antibody-
based immunotherapies (54,55).  
 
1.1.3 Epigenetical reprogramming of NK cells  
In the last decade, evidence has mounted that NK cells in certain situations can take on 
features of adaptive immunity. Early evidence for this was that certain CMV positive 
individuals had an NK cell pool that was strongly skewed towards subsets expressing 
NKG2C (35). Similarly, mouse NK-cells with a certain, antigen specific mouse CMV 
receptor, Ly49H, could mount a rapid and specific response upon a second challenge with the 
same virus (56). Moreover, different haptens and vaccines can induce long-lived liver NK-
cell populations with a degree of antigen specificity and an ability to respond quickly upon 
re-challenge, without any specific receptor having been identified for these antigens (57).  
In humans, many infections as well as malignancies may induce a further expansion of 
reprogrammed NK cells than CMV does by itself (58–62). In the case of NKG2C+ 
reprogrammed NK cells, this effect is noted almost exclusively in CMV+ individuals (58–62), 
suggesting that prior priming with CMV might be necessary for this specific reprogrammed 
NK cell population. Other herpes viruses do not seem to have the same effect as CMV and 
the data for herpes viruses is generally somewhat contradictory. Herpes simplex virus type 2 
infections do not seem to skew the NK cell pool (63). In a study of NK cells from children 
being seropositive for one or both of Epstein-Barr Virus (EBV) and CMV, EBV seemed to 
further pronounce the NKG2C+CD57+ NK cell profile in CMV+ individuals (VII). This result 
has been opposed by another study investigating CMV positive and negative young adults 
undergoing acute EBV infections (64). In this study, EBV infection did not alter the size of 
the CMV-induced NKG2C+CD57+ NK cell populations. This apparent discrepancy might be 
due to the different study setups. In the first study, the order of infections was not known. 
Although unlikely, it is not impossible that NK cells are instead primed by EBV, so that a 
secondary challenge with CMV results in more pronounced NK cell skewing. Furthermore, 
in the first study, coinfection with CMV and EBV might represent a proxy-marker for a 
generally higher infectious load. This could possibly be due to different living conditions, e.g. 
different number of siblings, a factor that is not controlled in this study. In that case, other 
infectious agents than EBV could potentially explain the difference between the groups. 
Contrarily, immune systems of different individuals become increasingly diverse with age 
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(65). One could thus speculate that the additional effect of EBV infection on skewing of the 
NK cell population in the second study is so small that it, with its total of 15 subjects is 
underpowered to reject the null hypothesis.  
The phenotype and function of the expanded NK cell populations has been further 
characterized since the initial recognition of the CMV-correlated NKG2C+ NK cell 
populations. In patients undergoing hematopoietic stem cell transplantation where CMV 
reactivates, the NK cell pool becomes strongly skewed (66, VIII). Expanded NK cells from 
patients with CMV infection may express distinct KIR repertoires, including DAP12-
signaling activating KIRs (67). Importantly, the NK cell expansions are not always NKG2C 
positive, and can be more widely defined by the down-regulation of different signaling 
adaptors, including FcERg, EAT-2 and SYK (VIII). This phenotypical and functional switch 
is due to epigenetical reprogramming of the cells (VIII). The DNA methylation patterns of 
the expanded NK cells more closely resemble those of CTL than conventional NK cells 
(VIII). A key transcription factor involved is promyelocytic leukemia Zink finger protein 
(PLZF) (VIII). Notably, small populations of cells with a reprogrammed phenotype are also 
detected in a fraction of CMV negative individuals (VIII), possibly indicating that other 
infections can expand reprogrammed NK cell populations that might be phenotypically 
different from the populations induced by CMV.  
The reprogrammed NK cells are less efficient killers of activated autologous CD4 T-cells 
than conventional cells but more potent cytokine producers upon Fc receptor engagement 
(VIII). Furthermore, they divide rapidly when co-cultured with HCMV-infected monocytes 
together with anti-HCMV antibodies (VIII). The reprogrammed NK cells are also less 
dependent on hematopoietic stem cell repletion than their conventional counterparts, pointing 
to a substantial capacity for self-renewal or a longer life span. Individuals with heterozygous 
mutations in GATA2, that due to haploinsufficiency display age-related progressive loss of 
both myeloid and lymphoid progenitor cells, retain reprogrammed NK cells also when all 
other NK cell compartments are depleted (IX). Furthermore, studies on paroxysmal nocturnal 
hematuria patients with hematopoietic, acquired somatic mutations in the PIGA gene, that 
lead to loss of glycosylphosphatidylinositol (GPI)-anchors in stem- and progenitor cells and 
all cells derived from these, show that reprogrammed NK cells, also long after the mutations 
have occurred, retain their GPI anchors, pointing to an important non-stem cell dependent 
survival mechanism (X). These observations defy the general notions that these 
reprogrammed NK cells are short-lived and/or that they have reached a stage of “terminal 
differentiation”, where they cannot divide. 
 
 12 
1.1.4 CD8+ T cells in general and cytotoxic CD8+ T cells in particular 
The primary role of CD8+ T cells is to control that endogenous cells produce normal proteins. 
This is achieved through TCR recognition of MHC-I (in humans, HLA-I) molecules that 
express signal peptides from proteins generally produced in the same cell. The TCR complex 
is comprised of one TCRa/b, one CD3d/e and one CD3g/e heterodimer as well as one z/z 
homodimer (68). Upon ligand binding, the activating signal is transmitted through a number 
of ITAM motifs on the CD3 subunits (68), as the TCR chains do not possess any cytoplasmic 
signaling motifs (68). 
The CD8+ T-cells are often stratified into naïve, central memory, effector memory and 
cytotoxic subgroups based on their expression of CD45RA, CD28, CCR7 and effector 
molecules amongst others (69,70). Even though such models are based on the phenotypic 
subsets in blood and are not always congruent with findings associated in well-controlled 
infections, such as infections with live vaccines (70), an attempt to delineate a typical CD8+ T 
cell activation and differentiation will follow.  
Naïve CD8+ T cells are cells that have undergone rigorous selection to be non-self-
reactive, but have not so far been exposed to their antigen. They express the chemokine 
receptor CCR7. As the chemokines for this receptor is abundantly expressed in secondary 
lymphoid organs, naïve CD8+ T cells in circulation always re-enter, or home, to these. In the 
secondary lymphoid organs, naïve CD8+ T cells interact with many professional antigen 
presenting cells. Subgroups of professional antigen presenting cells can namely ingest non-
endogenously produced proteins and present these on their HLA-I molecules, in a process 
called cross-presentation. When a naïve CD8+ T cell interacts with a professional antigen 
presenting cell that displays a peptide that it recognizes and gets co-stimulation through 
CD28, it becomes properly activated and starts dividing, mainly creating effector cells. The 
effector cells have high levels of cytotoxic proteins and lack CCR7 expression, and therefore 
no longer home to secondary lymphoid organs, but can migrate to the site of inflammation 
and perform their functions. After the initial infection has ceased, a number of memory T cell 
subsets are retained, among which a subgroup in the blood has remaining cytotoxic potential, 
and are called effector memory cells. Upon a second stimulus with antigen, these memory 
populations rapidly expand and give rise to effector cells, creating a robust response, 
generally diminishing the clinical effect of the second infection. 
In any individual, multiple developments from naïve cells to memory cells have taken, 
and are taking place, due to recently passed as well as chronic infections. In healthy 
individuals, there is for this reason a pool of cytotoxic CD8+ T cells with different phenotypes 
present at any given time. In models of CD8+ T cell differentiation, these are generally pooled 
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and denoted the effector-memory population. As a subpopulation of these cells re-express the 
naïve T cell marker CD45RA, they are often referred to as effector memory T cells with 
CD45RA or TEMRA, which are considered the most differentiated. Yet, composition of the 
effector-memory population varies greatly between individuals (see Supplementary figure 1, 
study 2 for example). For this reason, we will herein not attempt to separate the different 
CD8+ T cell populations with a cytotoxic potential, but instead denote them all cytotoxic 
CD8+ T lymphocytes, or CTL. Further characterization of these cells for comparative and 
diagnostic purposes is provided in Study 2. 
 
1.1.5 Shared traits among cytotoxic lymphocyte subsets  
Even though cytotoxic lymphocytes use distinct receptors for their activation, their effector 
machinery, from integration of the activating signals to the release of the cytotoxic proteins, 
is largely similar.  
Adhesion by integrins represent one of the first crucial steps in productive function of 
cytotoxic lymphocytes. Integrins are required for extravasation into tissues upon responses to 
infections, but also play important roles in establishing the contact site between the target cell 
and the cytotoxic lymphocyte, often denoted the “immune synapse”. Integrins are 
heterodimers consisting of one alpha and one beta subunit. An integrin central to cytotoxic 
lymphocyte function is leucocyte functional antigen 1 (LFA-1) (71). In LFA-1, both subunits 
have one knee, but the binding head is present in the alpha subunit (71). Integrins have three 
prototypic conformations. When the cell is not activated, the two subunits are bent and 
closely associated, generating a conformation with low ligand affinity. The molecule can also 
extend its knees, but retain low affinity, as the head is still bent down (71). However, if 
activating receptors are engaged, inside-out signals to the integrin induce a spatial separation 
of the cytoplasmic domains of the subunits that result in extension of the head, which 
increases the affinity for the ligand tremendously, in the case of LFA-1 10,000-fold (71). 
Interaction with multiple different activating receptors can generate this effect, and it occurs 
even if the receptor stimulus is not strong enough to induce release of cytotoxic granules (16). 
While strong stimuli can induce release of cytotoxic granules from cytotoxic lymphocytes 
also in the absence of LFA-1-ligand interactions, such release is poorly directed. LFA-1 is 
needed to recruit cytotoxic granules to the immune synapse, concentrating the release of their 
contents towards target cells, both increasing efficiency and decreasing bystander killing (16). 
Thus, LFA-1 plays a pivotal role in the effector functionality of cytotoxic lymphocytes.  
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Many other activating and inhibitory receptors associated with NK cells are also 
expressed on CTL, e.g. NKG2A, NKG2C and DNAM-1. NKG2A can partially inhibit, 
whereas NKG2C can potentiate TCR activation of T cell subsets expressing these receptors 
(72). DNAM-1 is widely expressed on CTL and functions as a co-activating receptor (45). 
Cytotoxic lymphocytes also all express a set of proteins that confer cytotoxicity. These 
are retained in so-called cytotoxic granules, a type of secretory lysosome. Three of these 
proteins are perforin, granzyme A and granzyme B. Perforin acts to create pores in the 
membrane of the target cell (73), allowing entry of other apoptosis-inducing enzymes, such as 
the granzymes (73) and that in addition gives rise to cellular stress by itself. Upon entering 
the target cell, granzyme A mainly cleaves enzymes involved in DNA repair while granzyme 
B activates the caspase cascade (74).  
In addition to having similar capabilities of responding with cytotoxicity upon activation, 
these cells also share the ability to rapidly produce and release large amounts of pro-
inflammatory cytokines, such as TNF and IFN-g when activated (75). They also recruit other 
cells by quickly releasing chemokines, such as CCL3 (MIP-1a) and -4 (MIP-1b) and -5 
(RANTES) (76,77).  
In summary, albeit typically defined as innate or adaptive lymphocytes, respectively, NK 
cells and CTL share intracellular mechanisms of signal integration and activation, adhesion, 
cytotoxic effector function and produce similar cyto- and chemokines.  
 
1.2 IMMUNODEFICIENCIES AND THE EVOLUTION OF THEIR DEFINITIONS 
 
For each uncommon, severe illness 
there is a common, subtle counterpart 
 
Traditionally, immunodeficiencies have been viewed as a group of rare, monogenetic defects 
with severe and early-onset clinical manifestations, resulting from the complete loss of a cell 
type or an immune function. Over time, mounting genetic evidence has challenged this view. 
Some investigators now argue that any disorder where the immune system plays a pathogenic 
role could be classified as an immunodeficiency (78). It has also been argued that, in the 
broadest sense, anyone being threatened by death by infection may harbor some form of 
immunodeficiency (78). Given the considerable variability in the human genes involved in 
immunity and especially as at least 100 genes are estimated to be deleteriously mutated at one 
allele in any healthy individual (79), it is hypothetically possible that for each human, there 
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might be a pathogen strain with the exactly right combination of virulence factors that during 
an infection would cause a gap between the otherwise overlapping immune functions, 
generating a situation-specific primary immunodeficiency.  
In the case of lymphocyte cytotoxicity, the prototypic associated immunodeficiency 
syndrome is termed hemophagocytic lymphohistiocytosis (HLH). This syndrome is, in its 
familial forms, caused by a complete loss of cytotoxic function (80). Typically, when 
presented with a viral infection early in life, the familial HLH patients’ inability to clear the 
virally infected cells and control the ensuing immune response leads to a state of hyper-
inflammation. In healthy individuals, such a hyper-inflammatory state would be terminated 
by cytotoxic killing of hyper-activated immune cells, but due to the general lack of 
cytotoxicity, the immune system spirals out of control, leading to multi-organ failure and 
ultimately death if treatment with cytostatic drugs is not initiated (81). Presently, the only 
cure for familial HLH is allogeneic hematopoietic stem cell transplantation (82). There are 
multiple monogenetic causes for familial HLH. Whereas familial HLH type 2 is caused by 
mutations in PRF1, encoding perforin, the other known mutations affect genes of proteins 
required for trafficking and release of cytotoxic granules (80).  
In line with the rest of the immunodeficiency field, the notion of possible clinical 
presentations caused by defects in lymphocyte cytotoxicity is also changing. Although 
mutations in the genes causing familial HLH leading to complete loss of protein function 
generally have complete, early disease penetrance, patients with mutations in STXBP2 can 
show gastrointestinal problems and mild bleeding disorders in childhood but not present with 
HLH until adolescence (83). Moreover, patients with missense mutations in PRF1 leading to 
reduction of function have been shown to have variable presentations, including 
hematological malignancies, cytopenias, systemic autoimmunity and gastro-intestinal 
symptoms (84). Some patients with PRF1 missense mutations might not develop HLH or not 
have any symptoms at all (84). These studies and others have led to the establishment of a 
spectral view of mutations affecting lymphocyte cytotoxicity, where complete loss of 
function results in HLH, whereas reduction of function can cause variable phenotypes (85). 
This, in turn, has led to an increasing interest in studying disorders where a partial defect in 
cytotoxic lymphocyte function might be suspected.  
 
1.3 THE DILEMMA OF THE OPTIMAL EXPERIMENT 
Reproducible experiments are the cornerstone of all empirical research. When attempting to 
study common, and potentially subtle, counterparts to the uncommon severe 
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immunoregulatory disorders, there is an additional need for highly sensitive experiments. 
Still, weighing these two factors is not always straight-forward; assays that are sensitive are 
not per definition also reproducible. This is exemplified by the establishment of functional 
cytotoxic lymphocyte assays utilizing antibodies specific to the open conformation of the 
integrin LFA-1 (86, XI). The conformational change of integrins to their open, high affinity 
state is a read-out of very early activation of cytotoxic lymphocytes. As LFA-1 is expressed 
at high levels on all cytotoxic lymphocytes, this conformational change is readily detectable, 
rendering the assay highly sensitive to cytotoxic lymphocyte activation. Yet, this sensitivity 
causes low robustness: as the conformational change of LFA-1 can occur even after very 
weak activating signals, subtle experimental variations can lead to large differences in the 
amount of activation that is seen. This means that the signal-to-noise ratio, indicated by the z-
factor (87), varies greatly even between batches in the same experiment (Supplementary table 
1, Study 1). 
CD107a expression on NK-cells after stimuli, which is a central assessment in the 
cellular diagnostics of cytotoxic immunodeficiency syndromes, often shows a suboptimal 
signal-to-noise ratio (Supplementary table 1, Study 1), the reasons for which are not 
thoroughly established. In the cases where complete defects in exocytotic capacity is sought 
after, this does not present a problem, as the signal is always strong enough to provide a 
highly specific and sensitive difference between patients and controls (88). Still, in some 
instances, when NK cells are scarce, or if the aim is finding more subtle, partial defects in 
cytotoxicity, this variability becomes problematic. One potential source of variability in this 
context is the intake of pharmacological substances, many of which act on widely expressed 
receptors. Investigating the effect of pharmacological substances in clinical use on NK cell 
functions might thus contribute to understanding the variability. This represented the 
rationale behind study 1. In addition, identifying other primary human cytotoxic lymphocyte 
populations with a more robust CD107a expression upon stimulation might also prove useful 
in a diagnostic setting, which is the aim of study 2. 
 
1.4 MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME 
AND THE CONNECTION TO DEFECTS IN LYMPHOCYTE 
CYTOTOXICITY 
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a syndrome based on a 
number of clinical criteria. The main characteristic is post-exertional neuro-immune 
exhaustion (89), i.e. that ME/CFS patients after physical or psychological stress experience 
 17 
flares. These flares are commonly characterized by influenza-like symptoms and neuro-
hormonal disturbances in addition to severe fatigue and typically go on for days to weeks 
(89). In a majority of ME/CFS cases, there is a connection between the onset and infections. 
In a prospective study in 196 primary care centers in Australia, all patients presenting either 
with infections by EBV, Ross River Virus or the intracellular parasite Coxiella burnetti, or 
having typical infectious symptoms, but without an identified agent, were followed with 
diagnostic ME/CFS questionnaires over time. After 6 month, 11% of either group of patients 
fulfilled the criteria for ME/CFS. There was no correlation to any specific agent, but rather a 
correlation to the severity of the initial disease episode (90). There are also numerous reports 
on epidemics of ME/CFS, both in direct association with known epidemics and where no 
associated pathogen has been identified (91–93). As cytotoxic lymphocytes are implicated in 
the defense against intracellular infections, they were hypothesized to be involved already 
when the syndrome was defined (94,95). Multiple studies have shown that cytotoxic 
lymphocytes are indeed abnormal as measured by lower killing of target cells or lower 
perforin expression, or that they are less abundant than in healthy individuals (94–96). Yet, 
negative results have conflicted the field (97,98), and critical reviews have even argued that 
there is a negative correlation between the overall quality of the studies and the number of 
findings (99), suggesting a publication bias. Still, as patients with mutations in STXB2, if not 
previously exposed to EBV, can get severely ill by mononucleosis in adolescence (83) and 
other, more subtle symptoms may arise in patients with missense mutations in familial HLH 
genes (84), it seems possible that a subgroup of ME/CFS patients indeed have a mild defect 
in lymphocyte cytotoxicity that may explain their symptoms. Moreover, as infections in 
general and CMV in particular are known to trigger epigenetically altered expansions of NK 
cells, and these changes in turn render the cells less efficient immune modulators and more 
targeted towards combatting infection (VIII), certain cases of ME/CFS could hypothetically 
be explained by excessive expansions of such reprogrammed NK cells. Finally, as patients 
with ME/CFS show imbalances in the hypothalamus-pituitary-adrenal axis (100) and altered 
catecholaminergic responses (101,102), their hypofunction in NK cells could also be due to a 
pathological interplay between the humoral stress response and the cellular immune 
responses.  
In summary, thorough investigations of cytotoxic lymphocyte functions in ME/CFS are 
warranted. This is the focus of study 3. 
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1.5 ROLES FOR NK CELLS IN SYSTEMIC LUPUS ERYTHEMATOSUS  
Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder. Amongst the more 
well-known symptoms of SLE are sun sensitivity and a typical butterfly-shaped rash of the 
face, that occurs in 30-60% of the cases. Other organ systems often affected are the kidneys, 
joints and the nervous system, but most organs can be affected in this heterogeneous disorder. 
Typical for SLE is a development of a wide range of autoantibodies, amongst which the most 
clinically screened for are so called anti-nuclear antibodies directed towards multiple 
disparate nuclear antigens. Albeit not specific to SLE patients (103), ANA are in the context 
of SLE hypothesized to arise as a response to an imbalance between apoptosis and clearance 
of apoptotic cells (104). The importance of this imbalance is underscored by the identification 
of monogenetic defects in the complement system leading to early-onset SLE (104).  
Amongst the different ANA, antibodies binding RNA are typical for SLE (103). These give 
rise to RNA-antibody immune complexes (RNA-IC), which contribute to the SLE 
pathogenesis in various ways, including aggregating in the kidneys, causing damage (105). In 
total, more than 180 different autoantibody specificities have so far been described, which is 
more than in any other autoimmune disorder (106). 
A phenomenon that is associated with the pathology of SLE is increased levels of IFN-a. 
While most human cells can express small amounts of IFN-a in response to IFN-a stimuli, 
the main a priori IFN-a producers are plasmacytoid dendritic cells (pDC) (107). A strong 
stimulus for pDC is RNA-IC, which is detected mainly via TLR7 (104). Intriguingly, if pDC 
can interact with NK cells in vitro, their production of IFN-a upon stimulation with RNA-IC 
is potentiated a 1,000-fold (108). This interaction is in part mediated by soluble factors, such 
as CCL4, but is also LFA-1 dependent (108). The SLAM family members CD229 and 
CD319 are possibly also involved in the pDC-NK cell interaction as they are up-regulated on 
pDC and NK cells after in vitro co-incubation with RNA-IC (VI). The activating adaptor 
molecules SLAM Associated Protein and EAT-2 are not expressed in pDC, likely rendering 
these receptors inhibitory (VI). The possible interaction between NK cells and pDC through 
SLAM family receptors might be dysregulated in SLE, shown by lower baseline SLAM 
family receptor expression in SLE patients (VI) and the genome-wide association studies 
linking the 1q23 locus, where the SLAM genes are present to SLE (109). Analogous findings 
have also been made in mice (110).  
Patients with SLE generally have fewer NK cells with lower cytotoxic capacity, and an 
activated NK cell phenotype (111). They also express higher levels of NKG2A and NKG2C 
as well as certain KIR receptors and react with stronger pro-inflammatory cytokine 
production upon stimulation (111). This, in combination with their capacity in potentiating 
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IFN-a production from pDC, has led to the hypothesis that NK cells are involved in the 
pathogenesis of SLE. Underscoring this, cases with very early-onset SLE have been reported 
in patients with biallelic missense mutations in perforin (84). Furthermore, amongst the few 
monogenetic causes of SLE-like disorders, mutations in FASLG, encoding Fas ligand, and 
fas, encoding the Fas receptor, are present in SLE patients and mouse models, respectively 
(104). Fas ligand is in resting state primarily expressed in cytotoxic lymphocytes, which can 
induce apoptosis by engaging Fas on target cells (112).  
Further building on the hypothesis of an NK cell involvement in SLE pathogenesis, 
study 4 and 5 aims at investigating the functional impact of autoantibodies to NKG2A and -C 
receptors in SLE patients.  
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2 ETHICAL CONSIDERATIONS 
All studies in this work have been performed with human cells. For this reason, ethical 
approval has been obtained before the start of each study. In the cases where blood from 
healthy human donors has been used, informed, oral consent has been received. As these 
individuals were de-identified, no results have been reported back to them. For all 
experiments involving patient material, written informed consent was obtained.  
In the case of Study 3, there was an interest from a few patients in retrieving their 
personal study results. This led to thorough discussions due to an ethical dilemma: in 
accordance with the patient information, the individual patients had the right to retrieve the 
personal results if these could improve the clinical outcome of the individual. On the other 
side, the results of an individual are generally hard to interpret, both as normal intervals are 
lacking and as a seemingly “pathological” phenotypes or functional responses are, in most 
cases, very hard to directly associate to clinical symptoms. In the end, the patients urging to 
know their results have gotten an interpretation of these, coupled with information regarding 
the uncertainty of the results. The interpretation was performed by Dr Yenan Bryceson and 
myself together in each instance to leave minimal room for over-interpretation. In one case, 
where the p.A91V variant of perforin was present in a homozygous form, the patient was 
actively contacted and referred to clinical genetics, to further explore the possible influence of 




3 INTRODUCTION TO METHODS AND MATERIALS 
3.1 MULTICOLOR FLOW CYTOMETRY 
For the non-flow cytometrist, a short introduction to this technique might be necessary to 
follow the experimental work in these studies. Flow cytometry is the art of investigating 
individual cells in suspension, by fluxing them through a thin chamber, wherein their 
characteristics can be assessed using electrochemical methods. Most commonly, the cells 
have been pretreated by incubation with fluorophore-conjugated antibodies that bind specific 
antigens on the cell surface or in intracellular compartments. Fluorophores are fluorescent 
biomolecules. When cells covered with such antibody-fluorophore conjugates flow through 
the detection chamber of the flow cytometer, they are illuminated with lasers that excite the 
fluorophores, that subsequently emit specific signals that are captured by detectors. With this 
method, the strength of the signal emitted by a certain fluorophore corresponds to the amount 
of bound antibody-fluorophore conjugates on the cell, which by itself is a proxy marker for 
the amount of protein. Due to the discovery of a multitude of fluorophores, up to 30 such 
assessments can be done simultaneously for one cell, and thousands of cells can be 
investigated every second. This efficient generation of complex data has rendered flow 
cytometry a vital tool for immunologists, but it has been made possible partially on the cost 
of robustness. First, the method is sensitive to day-to-day variation in the optics of the flow 
cytometer itself, but also to the state of the antibody-flurophore conjugates, on top of the 
variability caused by slight perturbations of the experimental procedures preceding the flow 
cytometry assessment. Secondly, standards to calculate how much protein a certain signal 
corresponds to are hard to obtain. Consequently, flow cytometry is best suited for extensive 
experiments on small sets of patients and controls (<100) analyzed together. 
 
3.2 PERIPHERAL BLOOD MONONUCLEAR CELLS 
In almost all the experimental work in this thesis, peripheral blood mononuclear cells, or 
PBMC, are used. PBMC are made up of lymphocyte and monocyte subsets mainly. PBMC 
are obtained from whole blood by density-gradient centrifugation, utilizing the lower density 
that PBMC show compared to red blood cells or neutrophils. The isolation is performed to 
enable long-term experiments, freezing of cells and to reduce the effect of the external 
environment but not completely exclude the physiological possibility of cell-cell interactions.   
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4 RESULTS AND DISCUSSION 
4.1 STUDY 1 
 
A step towards controlled constancy lies in 
understanding the grounds of variability 
 
A common, yet often underestimated source of bias in functional immunological studies is 
pharmacological treatments. A majority of available drugs show significant 
polypharmacology (113) and even recently developed specific inhibitors also exhibit off-
target effects. Most patients with suspected immunodeficiencies are treated with multiple 
drugs. In cases where these drugs affect lymphocyte cytotoxicity, it might contribute to the 
pronounced inter-donor variability in cytotoxicity assays with clinical material. Lymphocyte 
cytotoxicity is known to be affected by multiple pharmacological treatments in vitro (114–
116) and in vivo (117,118). However, systematical screening of the effect of in-use 
compounds on primary human cytotoxic lymphocyte functions has not previously been 
performed.  
In an attempt to overcome this, Study 1 was conducted. Here, the impact of 1,200 in-use 
or previously used drugs on NK cell functions was investigated. First, PBMC isolated from 
one donor the previous day and rested overnight was pre-incubated with each drug 
individually. After 15 minutes, an anti-CD16 antibody as added to all PBMC-drug co-
cultures, and the cells were incubated for one hour, followed by staining and flow cytometry. 
Of the 1,200 drugs tested, 56 and 12 were identified as inhibiting and activating NK cell 
function, respectively.  
 In this study, the chosen screening concentration was 5 µM. This concentration is lower 
than the standard 10 µM (Thomas Lundbäck, personal communication and (119)) and it was 
agreed upon as a trade-off between ensuring that a number of hits would be identified and 
that toxicity would be limited. In hindsight, a lower screening concentration would possibly 
have been preferable as 5 µM is unphysiologically high for most substances, which might 
result in a– and b–errors. The a–errors were dealt with within the study, as a titration was 
performed for all hits. At 0.2 µM, 29 compounds retained more than 50% of their 5 µM 
activity, all of which were inhibitors (Table 1). The problem of b–errors is less well dealt 
with within the study. The high concentration of the substances namely resulted in significant 
toxicity or base line shifts for 26 substances, which were excluded from further testing (see 
 23 
Fig 2, Study 1). It is plausible that a fraction of these would have shown significant inhibitory 
or activating capacity at lower concentrations. 
Of the 29 inhibitors with retained significant activity at 0.2 µM, all but naftifine have 
been previously associated to inhibition of lymphocyte cytotoxicity (Table 1)(114–116,120–
123). It is worth noting that of all the 29 substances with strong inhibitory activity in the sub-
micromolar range, 19 had effects dependent on cAMP increase, underscoring the vital 
inhibitory role for cAMP in cytotoxic lymphocytes. This finding might also underscore that 
the selected hits in this assay are profoundly dependent on direct interference with activating 
signaling, which is likely a bias introduced by the short time-frame of the assay. If the drug 
pre-incubation time had been extended to a few hours, substances with effects on 
transcription, such as corticosteroid-derivatives would likely have been identified as hits 
(124). Of note, a majority of the substances identified in the screen, such as  b-adrenergic 
agonists and histaminergic antagonists, influence signaling pathways that are known to be 
important under physiological, non-pharmacologically influenced conditions. This was all 
taken into consideration in later work where understanding the grounds of variability turned 
out to be important (see Study 3). 
Table 1. Substances in Study 1 with retained activity at 0.2 µM 
 
Name Pharmagological group Likely mechanism Effects previously reportedon lymphocyte cytotoxicity
Isoetharine ADRB2 agonist cAMP increase Yes
Dipivefrin ADRB2 agonist cAMP increase Yes
Metaproterenol ADRB2 agonist cAMP increase Yes
Terbutaline ADRB2 agonist cAMP increase Yes
Racepinephrine ADRB2 agonist cAMP increase Yes
(-)-Isoproterenol ADRB2 agonist cAMP increase Yes
Formoterol ADRB2 agonist cAMP increase Yes
Levalbuterol ADRB2 agonist cAMP increase Yes
Fenoterol ADRB2 agonist cAMP increase Yes
Clenbuterol ADRB2 agonist cAMP increase Yes
Salmeterol ADRB2 agonist cAMP increase Yes
Ibudilast PDE4I cAMP increase Yes
Zardaverine PDE4I cAMP increase Yes
Rolipram PDE4I cAMP increase Yes
Ethaverine PDE-inhibitor cAMP increase Yes
Misoprostol prostaglandin cAMP increase Yes
Alprostadil prostaglandin cAMP increase Yes
Desloratadine HRH1 inhibitor PLC inactivity (?) Yes
Chlorprothixene phenotiazine Calmodulin inhibition (?) Yes
Norcyclobenzaprine phenotiazine Calmodulin inhibition (?) Yes
Zuclopenthixol phenotiazine Calmodulin inhibition (?) Yes
Thiethylperazine phenotiazine Calmodulin inhibition (?) Yes
Moricizine phenotiazine derivative Calmodulin inhibition (?) Yes
Clomipramine Tricyclic antidepressant cAMP increase possible Yes
Sertraline Specific serotonin reuptake inhibitor cAMP increase possible Only indirectly
Nisoldipine L-type Ca channel blocker Likely Ca-dependent Yes
Naftifine fungal ergosterol synthesis inhibitor Not clear No
Tracazolate GABAA-inhibitor Not clear Yes
Cyclosporin A Calcineurin inhibitor Calcineurin inhibitor Yes
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4.2 STUDY 2 
 
The subtle in the macrocosm may be discerned by 
finding the robust in the microcosm 
 
As discussed in the introduction, an alternative to NK cell degranulation for diagnostic 
purposes of immunodeficiency syndromes involving lymphocyte cytotoxicity has been 
sought for. In clinical practice, stable, widely distributed flow cytometers were for long 
limited to four simultaneous assessable markers. As the three markers CD3, CD56 and 
CD107a had already been included in the diagnostic panel for evaluation of lymphocyte 
cytotoxicity, attempts at identifying a fourth marker that could differentiate a diagnostically 
useful subpopulation was made. This led to the early testing of CD3+CD8+ T cell CD107a 
expression as an additional marker (88). However, investigating CD107a expression in bulk, 
unactivated CD8 T cells did not prove to give sufficient signal-to-noise ratio, likely due to 
inter-donor variations in the size of the cytotoxic fraction of total CD3+CD8+ T cells. To 
circumvent this, strategies investigating CD107a expression in CD8 T cell blasts came into 
practice, but have not been widely implemented due to large day-to-day variability and 
insufficient blast generation in samples from immune-suppressed patients (88). Establishment 
of a robust and preferably simple marker setup for definition of CTL for diagnostic settings 
could thus potentially prove to be an example of finding the robust in the microcosm.  
To attempt this, Study 2 was undertaken. Here, it was shown that among a number of 
investigated extracellular markers, CD57 was most strongly positively correlated to 
expression of cytotoxic proteins, in line with previous studies (125). When comparing 
CD8+CD57+ T cells to NK cells, CD8+CD57+ T cells expressed cytotoxic proteins to the 
same extent, and upon stimulation they released cytotoxic granules, TNF and IFN-g in higher 
and more reliable numbers than NK cells did. Finally, it was shown that for familial HLH 
patients, the same pattern of loss or reduction of cytotoxic function was seen in CD8+CD57+ 
T cells as in NK cells.  
That CD57 is a useful marker for cytotoxic lymphocytes has been clear since its 
identification in 1981 (126). Some early definitions of cytotoxic lymphocytes even used 
CD57 as the only defining marker, thus not separating NK and CTL (127). With this in mind, 
it was attempted to substitute CD8 with CD57 in the diagnostic definition of CTL, which 
indeed was more useful than CD8 alone (see supplementary figure S4, Study 2).  
After the publication of Study 2, it has been shown in clinical materials that the 
sensitivity and specificity of identifying primary defects in the release of cytotoxic granules 
 25 
by investigating degranulation by CD3+CD8+CD57+ T cells is 97 and 95 percent, respectively 
(128), making it, by itself, superior to investigating NK cell degranulation. The combination 
of the two leads to even further increases in diagnostic usefulness (Samuel Chiang et al, 
manuscript in preparation), providing evidence that investigating CD8+CD57+ T cells for 
diagnostic purposes in the contexts of immunodeficiencies involving lymphocyte cytotoxicity 
indeed represents something robust in the microcosm. 
 
4.3 STUDY 3 
 
For each uncommon, severe illness 
there is a common, subtle counterpart 
 
The identification of missense mutations in cytotoxicity genes giving rise to milder 
phenotypes (84) and the establishment of robust cytotoxicity evaluations, led to an interest in 
identifying syndromes that could represent an example of a common, subtle counterpart to 
familial HLH. As discussed in the introductory section, with its connection to viral infections 
and compelling but inconclusive data on NK cell aberrances, ME/CFS seemed to be a 
suitable candidate syndrome for this purpose. Therefore, Study 3 investigated cytotoxic 
lymphocyte function and phenotype in ME/CFS patients. To study this patient group and the 
subtleties that were hypothesized to separate them from controls, samples from all study 
subjects were simultaneously assessed, to avoid batch effect. Further, to increase the external 
validity of the findings, a setup with two substudies was chosen, where all findings identified 
in samples from one cohort were validated in samples from another cohort.  
In this study, no reproducible differences were noted in the number of cytotoxic cells in 
whole blood, the cytotoxic granule constituents, nor in the ability to release cytotoxic 
granules. Further, no differences were noted in the killing or the cytokine production capacity 
of the cells.  
As a link between the acquisition of the syndrome and viral infections was established 
(90) and as NK cells in certain individuals had been shown to be epigenetically 
reprogrammed by viral infections, which dampened their immunoregulatory capacity (VIII), 
it was hypothesized that the noted hypofunction could be due to aberrances in the sizes and 
frequencies of such reprogrammed NK cell compartments among the ME/CFS patients. This 
was tested and turned out not to be the case.  
When all tested inherent, direct functions of the cytotoxic lymphocytes had been 
assessed and turned out normal, a thorough review of the methodology in the previous NK 
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cell reports in the field was conducted (see Supplementary Table 4 of Study 3). From this 
overview, it was clear that all previous functional NK cell experiments had been conducted in 
either whole blood or directly after isolation from whole blood, thus allowing for serum 
factors to influence the functions. One compelling group of such factors is catecholamines. 
Numerous reports, including Study 1, have shown that cytotoxic lymphocytes in general, and 
NK cells in particular, are inhibited by stimulation through the  b2-adrenergic receptor (114). 
In addition, ME/CFS patients have been shown to have abnormal catecholaminergic stress 
responses (102). Considering this, it was investigated whether NK cells from ME/CFS 
individuals responded differently to a common stimulus, in this case anti-CD16 antibody 
stimulation, during suppression of functions by co-incubation with adrenaline. Indeed, a 
difference in response, where the ME/CFS patients showed less inhibition and hence stronger 
responses towards anti-CD16 antibodies was seen among the patients in the first substudy. 
Due to experimental error, this experiment could not be validated in the second substudy, but 
our findings substantiate those of a previous study (101). To further explore the possible 
effects of serum factors on cytotoxic lymphocyte function in ME/CFS patients, serum-
transfer experiments could be conducted, where PBMC from healthy individuals would be 
co-incubated with serum from patients and from controls. If the serum from the patients 
indeed would dampen lymphocyte cytotoxicity, selected antagonists towards receptors likely 
to contribute to this inhibition could be used in the co-cultures. If such an antagonist could 
reverse the effects of the serum, the serum factor responsible for dampening of ME/CFS 
patient lymphocyte cytotoxicity could be identified.  
As no differences were found on the group level, the focus was instead turned to a search 
for subgroups or single individuals with aberrant phenotypic or functional traits. No 
subgroups were visual in any single immune parameter. One individual was identified that 
expressed lower levels of perforin in all investigated cell subsets, which was explained by 
biallelic expression of a common variant of the PRF1 gene, p.A91V. After this individual had 
been identified, a screen was performed for this variant in 41 of the study patients where 
DNA was available. This showed that the overall allele frequency of this variant was in 
normal range (7.3%), compared to a population study with 30,000 European individuals 
(4.7%) (129). In the population study, the homozygous carriership frequency was 1 per 450 
individuals (129). This is the expected frequency according to the Hardy-Weinberg principle 
(130), minimizing the risk of a selection bias excluding sick homozygous carriers of p.A91V 
among the 30,000 individuals. Still, monoallelic and biallelic expression of this gene variant 
is associated with a risk of developing malignancies (Löfstedt et al, submitted) and 
homozygous carriers occasionally present with HLH-like symptoms (84). Notably, in a case 
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report, a patient homozygous for the PRF1 p.A91V variant acquired HLH during a 
tuberculosis infection (131). This patient had a monozygotic twin that did not suffer from 
tuberculosis and did not get HLH (131). Thus, the penetrance and the clinical presentations 
are variable, and with only one ME/CFS patient in the study showing this variant, it cannot be 
confirmed that it is implicated in the etiology of the disorder for this individual patient. Yet, 
this finding warrants population-based studies investigating a possible correlation between 
biallelic expression of the PRF1 p.A91V variant with symptoms associated with ME/CFS.  
In a final attempt to detect subtle differences between the groups, all common 
immunological parameters to both substudies were investigated together using a supervised 
dimensionality reduction approach. The used method, called sparse partial least squares 
discriminant analysis (132), identifies the vector through a multidimensional data cloud that 
maximally discriminates the pre-defined groups (in this case patients and controls). It then 
uses a penalty to exclude immunological parameters that do not contribute to this 
discriminant vector. This analysis was done for each substudy individually. After this, the 
resulting discriminant vectors were reconstructed for the other substudy in a cross-over 
manner, and used for prediction purposes. With this approach, the optimal separation was 
only between 60 and 70 percent sensitive and specific for the identification of individual 
patients, meaning that the groups are practically inseparable with the data from this study. 
Notably, though, only immune parameters that were present for a majority of patients and 
controls from both substudies were included in this analysis. Amongst others, this excluded 
the NK cell killing as well as the adrenergic inhibition assays. As the latter showed a 
significant trend towards separating the patients from controls by themselves, it is not 
impossible that adding these would have improved the sensitivity and specificity.  
Taken together, the results of this study did not identify reductions in cytotoxic 
lymphocyte function in all or a subgroup of ME/CFS patients. Nonetheless, as one patient 
identified by the screening was homozygous for a PRF1 variant with connections to HLH, it 
is possible that a small fraction of ME/CFS patients may indeed represent a subtle 
counterpart to familial HLH, but this needs to be further studied in larger materials. 
Moreover, with the hints towards a difference in the response to adrenergic stimuli, 
integrating the knowledge of how pharmacological substances and serum factors impact 
lymphocyte cytotoxicity may have contributed to understanding the grounds of variability, in 
this case the variability between studies. Lastly, by utilizing the robust in the microcosm, in 
this case the set of reproducible assays, we can, with some confidence, confirm that 




4.4 STUDIES 4 AND 5 
 
The regular nature of an illness may be understood 
by exploring its rare causes 
 
Being a classical autoimmune disorder, systemic lupus erythematosus represents another 
angle to the connection between primary immunodeficiencies and dysfunctions in 
lymphocyte cytotoxicity. A curious link between SLE and cytotoxic lymphocyte function is 
Study 4 that presents a patient with SLE harboring autoantibodies directed against NKG2A. 
This autoantibody was identified en passant during screening efforts to establish receptors 
implicated in the interaction between NK cells and plasmacytoid dendritic cells. When 
incubating NK cells with RNA-immune complexes (RNA-IC) with IgG obtained from this 
specific SLE patient, all NKG2A staining suddenly disappeared. The IgG solutions were in 
this case obtained from a plasmapheresis that the patient had undergone during a severe SLE 
flare. It was established that this effect was due to an autoantibody directed against NKG2A. 
This autoantibody blocked CD94/NKG2A binding of HLA-E, but did not interfere with 
CD94/NKG2C-HLA-E interaction. The abolishment of NKG2A-HLA-E interactions also 
had functional implications, as CD56bright and CD56dimNKG2C- cells, that are enriched for 
NKG2A+ cells, were not inhibited by HLA-E expression on target cells in the presence of 
IgG from the SLE patient. Furthermore, the presence of the autoantibody correlated with the 
SLE disease activity index (Spearman correlation 0.78). Thus, this NKG2A autoantibody 
seemed to underscore a potential role for NK cells in the SLE pathology.  
To further explore the presence of NKG2-autoantibodies in SLE, Study 5 was 
undertaken. Here, a screen of 212 SLE patients and 90 controls was performed. In this study, 
six additional patients harboring autoantibodies directed against NKG2A were identified, two 
of which showed cross-reactivity with NKG2C. For four of the patients, blocking of HLA-E-
NKG2A interactions was observed, whereas the serum from one patient enhanced HLA-E 
binding of both NKG2A and NKG2C. In accordance with their specificities, the different 
autoantibodies showed different functional profiles. When the cells from four of the patients 
were investigated, two showed unusually low NK cell numbers (1.9 and 2.3%, respectively), 
whereas two had normal numbers, but did not show any cells expressing NKG2A or NKG2C. 
As this could be due to either detection errors due to the presence of autoantibodies, or 
opsonization and subsequent deletion of NKG2A or NKG2C positive cells, the levels of 
NKG2A and NKG2C mRNA transcripts was measured in bulk isolated NK cells. The mRNA 
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levels were comparable between patients and controls, suggesting that the effect might be 
covering of the epitopes leading to detection error. Additional experiments however showed 
that cell lines expressing NKG2A or NKG2C were selectively killed by IL-2 activated PBMC 
when co-incubated with sera containing the specific autoantibodies, in favor of the hypothesis 
that the NK cells expressing NKG2A or NKG2C could be opsonized and killed. Clinically, 
the small subgroup of SLE patients expressing these autoantibodies had a more severe 
disease course than other SLE patients. The presence of autoantibodies also seemed to be 
more common during flares of the disorder for individual patients, but this was not 
statistically verified overall (Spearman correlation between the level of NKG2A antibodies 
and SLE disease activity index for all patients together was 0.25).  
Notably, in 2008 a patent was established for the use of Monalizumab, a humanized anti-
NKG2A antibody, as treatment for malignancies and autoimmune disorders (133). The 
rationale behind this was that blocking NKG2A would lead to dis-inhibition of NK cells and 
congruently to increased killing of neoplastic cells or more efficient immunoregulation, 
which is in line with studies of administration of NKG2A antibodies in mouse multiple 
sclerosis models (134). Early results indicated a good safety profile for patients with 
rheumatoid arthritis (unpublished data, but see (135)). Subsequently, the autoimmune 
indications have been dropped, but Monalizumab is currently being tested in clinical trials for 
a variety of malignancies (136). At a first glance, it might seem contradictory that an 
autoantibody with possible negative impact on the clinical outcome of a systemic 
autoimmune disease might be clinically useful and safe to administer in other related and 
unrelated syndromes. However, although the binding profile of Monalizumab and the NKG2 
autoantibodies are closely related, the Ig subclass is IgG4 for Monalizumab and IgG1 and 
IgG3 for the autoantibodies. This means that the Fc binding profile will be very different 
between the antibodies; whereas IgG1 and IgG3 binds all Fcg receptors, IgG4 is bound only 
by a fraction of Fcg receptors and generally with lower affinity. For example, only certain 
allele variants of FcgRIIIA/CD16 binds IgG4 at all (137). This will result in a lower risk of 
ADCC towards NKG2A expressing cells when Monalizumab is used compared to the 
situation with the autoantibodies. With this in mind, it might be argued that the most 
important way that the autoantibodies towards NKG2A might contribute to pathology is by 
clearance of NKG2A positive cells, but this would need to be further proven.  
Taken together, the results of Study 4 and 5 show that a fraction of SLE patients possess 
autoantibodies to NKG2 receptors. These autoantibodies are, at least in certain individuals, 
correlated to clinical symptoms and have functional impact on a cellular level, possibly 
representing a rare cause of SLE flares. These findings warrant further studies of NK cell 
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involvement in SLE. One current path of follow up is widening the screening efforts to detect 
autoantibodies directed against other NK cell receptors, especially KIRs. This would be in 
line with previously reports (138) and preliminary data on patients in the already screened 
group indicate presence of such autoantibodies (139).   
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5 CONCLUSION 
Currently, the number of identified disease-correlated immunophenotypic aberrances is 
increasing rapidly. Still, a causal link between patient symptoms and immunologic aberrances 
is seldom identified. This inevitably leads to a growing gap between the number of possible 
and confirmed immunodeficiencies. To narrow this gap, methodologically sound, and 
carefully interpreted studies on immune cell phenotype and function on well-defined patient 
groups are needed.  
In this work, Study 1 and 2 contribute to establishing a framework for assessing and 
interpreting the function of cytotoxic lymphocytes from patients with potential defects in 
cytotoxicity. Study 1 identifies a set of clinically used molecules with acute effects on 
cytotoxic lymphocyte function, and as a by-effect underscores the pivotal role of  b-
adrenergic stimuli in the regulation of cytotoxic lymphocyte function. Study 2 instead 
establishes CD57 as a robust identifier for cytotoxic T-cells in diagnostic experimental 
setups.  The last three studies investigate cytotoxic lymphocyte function in patient groups. In 
Study 3, no evidence for a general primary defect in cytotoxic lymphocytes from myalgic 
encephalomyelitis patients is found. In Study 4 and 5, a subgroup of patients with systemic 
lupus erythematosus are identified that express peculiar autoantibodies directed against 
cytotoxic lymphocyte receptors, which are shown to have functional implications. 
In conclusion, these studies attempt to narrowing the gap between the suspected and 
confirmed immunodeficiency syndromes. In that, they arguably all, by their own means, 
contribute to the gaining of salutogenetic insights by finding the traits defining, or not 






6 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Detta arbete söker på olika sätt belysa hur nedsatt funktion hos en grupp immunceller, kallade 
cytotoxiska lymfocyter, kan tänkas inverka på förloppet vid olika sjukdomstillstånd. De 
cytotoxiska lymfocyterna har den huvudsakliga uppgiften att identifiera och döda infekterade, 
cancerösa eller överaktiverade celler i kroppen, så att dessa problem inte sprids vidare. Om de 
cytotoxiska lymfocyterna inte fungerar som de ska, kan det följaktligen leda till att 
infektioner eller cancer sprids, eller att autoimmuna problem får fäste. Det är fördjupad 
förståelse av dessa cellers roll i olika sjukdomar som står i fokus för denna 
doktorsavhandling. Alla delarna i avhandlingen utgår i grunden från ett forskningsmässigt 
tillvägagångssätt där patienter med liknande symptom grupperas och deras immunförsvar 
jämförs dem emellan och med friska kontroller. När systematiska avvikelser identifieras hos 
patienterna i en sådan grupp, görs försök att koppla samman dessa med utvecklingen av de 
symptom de har gemensamt. När ett sådant samband kan säkerställas, innebär detta dels att 
den identifierade avvikelsen kan bli mål för behandlingar. Det bidrar dock också till att öka 
förståelsen för hur immunförsvaret arbetar med att skydda oss andra från att insjukna på 
samma sätt som patienterna med den identifierade avvikelsen. Detta sammanfattas i den 
första av fem maximer som kondenserar de mest väsentliga underliggande tankarna bakom 
detta arbete:  
Salutogenetisk insikt (kunskap om vad som gör oss friska) 
kan nås genom att finna drag definierande varje grupp sjuka  
 
En kort resumé av studierna: 
Den första studien handlar om hur 1500 vanligt förekommande läkemedel påverkar de 
cytotoxiska lymfocyternas funktioner. Flera grupper av läkemedel identifieras som har extra 
stor påverkan, av vilka den dominerande gruppen är adrenalinrelaterade substanser. 
Medvetenhet om dessa läkemedels inverkan på cellfunktionen är viktig att ha i tolkning 
experimentella data från såväl läkemedelsbehandlade som akut stressade patienter. I den 
andra studien etableras en ny diagnostisk metod för att hitta genetiska avvikelser som 
påverkar cytotoxisk lymfocytfunktion. Den tredje studien undersöker huruvida patienter med 
myalgisk encefalomyelit/kroniskt trötthetssyndrom (ME/CFS) visar tecken på nedsatt 
cytotoxisk lymfocytfunktion, vilket inte visar sig vara fallet, utom möjligen i en av 48 
patienter. De två sista studierna handlar om autoantikroppar mot receptorer uttryckta på 
cytotoxiska lymfocyter; hur sådana antikroppar dels påverkar cellfunktioner, och dels om det 
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finns en koppling mellan sådana antikroppar och skov i systemisk lupus erytematosus (SLE), 
en autoimmun sjukdom.  
I en tillvaro med allt bättre möjligheter att göra komplexa genetiska och proteinbaserade 
tester, hittas allt fler korrelationer mellan immunförsvarsavvikelser och olika sjukdomar. 
Antalet säkerställda kopplingar mellan immunförsvaret och sjukdomens uppkomst, där en så 
kallad immunbrist kan sägas föreligga, ökar dock inte i samma takt. Detta bidrar till att skapa 
ett växande gap mellan de misstänkta och de säkerställda immunbristproblemen. 
Sammantaget söker studierna i denna avhandling först skapa goda förutsättningar för att göra 
bra tolkningar av experimentella data och sedan undersöka såväl ME/CFS som SLE med 
hjälp av dessa förbättrade förutsättningar. De syftar därför till att i möjligaste mån minska 
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